Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-13

Clinical Trial Update: A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention [Phase 2]

View source ↗

Summary

Phase 2 trial update for AMG 334 in migraine prevention has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMG 334 (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2019-03-13